Bicalutamide (Casodex)

General information

Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor that competitively inhibits androgens by binding to cytosol androgen receptors.^[1]^[2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Prostate cancer

Patient drug information

History of changes in FDA indication

1995-10-04: Initial accelerated approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced prostate cancer. (Based on Schellhammer et al. 1995)
- 1997-12-12: Converted to regular approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced prostate cancer. (Based on Schellhammer et al. 1995)

History of changes in EMA indication

1995-02-28: EURD

History of changes in Health Canada indication

1995-11-02: Initial notice of compliance for use in combination therapy with either a luteinizing hormone releasing hormone (LHRH) analogue or surgical castration in the treatment of metastatic (Stage D2) prostate cancer.

Also known as

Brand names: Bical, Bicalmid, Bicalon, Bicatero, Binarex, Casodex, Cassotide, Cosudex, Calutide, Kalumid, Procalut, Prosmide, Utamide

References

[insert-1] 1.0 ^1.1 ^1.2 Bicalutamide (Casodex) package insert

[2] Bicalutamide (Casodex) package insert (locally hosted backup)

[3] Bicalutamide (Casodex) patient drug information (Chemocare)

[4] Bicalutamide (Casodex) patient drug information (UpToDate)

[1]

[2]

[3]

[4]